Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
| Author | |
|---|---|
| Abstract |
:
Salvage chemotherapy for recurrent chest wall lesions in breast cancer results in response rates of 20% to 30%. Preclinical studies showed significant disease regression could be induced in murine chest wall mammary cancers with a topical toll-like receptor (TLR)-7 agonist, imiquimod. |
| Year of Publication |
:
2017
|
| Journal |
:
JAMA oncology
|
| Volume |
:
3
|
| Issue |
:
7
|
| Number of Pages |
:
969-973
|
| Date Published |
:
2017
|
| ISSN Number |
:
2374-2437
|
| URL |
:
https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2016.6007
|
| DOI |
:
10.1001/jamaoncol.2016.6007
|
| Short Title |
:
JAMA Oncol
|
| Download citation |
